Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 8.
doi: 10.1007/s12035-025-05189-6. Online ahead of print.

Exosome-Mediated Delivery of Amyloid Beta Modulators: A Potential Therapeutic Strategy for Alzheimer's Disease

Affiliations
Review

Exosome-Mediated Delivery of Amyloid Beta Modulators: A Potential Therapeutic Strategy for Alzheimer's Disease

Tehreem Mushtaq et al. Mol Neurobiol. .

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the deposition of amyloid-beta (Aβ) plaques and tau protein abnormalities, disrupting synaptic function and causing progressive cognitive decline. However, significant efforts in research are still hampered by current treatments, which are limited by poor penetration of the BBB and non-specific effects. Recent developments in nanotechnology and drug delivery have found exosomes as innovative carriers targeting Aβ. They have identified a novel approach to treating the underlying pathology of AD. Exosomes are naturally occurring extracellular vesicles with several unique advantages. They are biocompatible, can cross the BBB, and can be engineered to deliver therapeutic agents with precision. These agents range from small interfering RNA (siRNA), peptides, or drugs designed to either inhibit Aβ aggregation, enhance its clearance, or regulate the genes involved in its production. Among these agents, neural-derived exosomes offer great promise as they naturally attract neuronal tissue and, therefore, increase the specificity of the treatment. In preclinical studies, such therapies have proven encouraging by demonstrating reduced Aβ accumulation, a decrease in neuroinflammation, and cognitive improvement in models of AD. However, translation into clinical application faces some challenges, such as development of scalable methods of exosome production, drug loading efficiency, stability, and safety upon administration. The present review takes an outlook toward the growing area of targeting Aβ pathology via exosomes with potential benefits, recent breakthroughs, and open challenges. Harnessed therapy from exosomes can create groundbreaking-therapies in treating AD that hope for millions to come out from this devastator disease.

Keywords: Alzheimer’s disease; Amyloid plague; Amyloid precursor protein; Amyloid-beta; Exosomes; Extravesicular vesicles.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical Approval and Consent to Participate: Not applicable. Institutional Review Board: Not applicable. Informed Consent: Not applicable. Competing interests: The authors declare no competing interests.

References

    1. Gomes P et al (2022) Extracellular vesicles and Alzheimer’s disease in the novel era of precision medicine: implications for disease progression, diagnosis and treatment. Exp Neurol 358:114183 - PubMed - PMC - DOI
    1. Lanctôt KL et al (2017) Neuropsychiatric signs and symptoms of Alzheimer’s disease: new treatment paradigms. Alzheimer’s & Dementia: Translational Research & Clinical Interventions 3(3):440–449 - DOI
    1. Better MA (2023) Alzheimer’s disease facts and figures. Alzheimers Dement 19(4):1598–1695
    1. Ehrenberg AJ et al (2018) Neuropathologic correlates of psychiatric symptoms in Alzheimer’s disease. J Alzheimers Dis 66(1):115–126 - PubMed - PMC - DOI
    1. Azargoonjahromi A (2024) The duality of amyloid-β: its role in normal and Alzheimer’s disease states. Mol Brain 17(1):44 - PubMed - PMC - DOI

LinkOut - more resources